https://www.pharmaradar360.com/article/celldex-reports-positive-phase-3-results-for-barzolvolimab-in-chronic-spontaneou-0017f5ea9d432ed0PharmaRadar360en2026-09-22T11:00:00.000ZCelldex Reports Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticariahttps://www.pharmaradar360.com/article/bofa-securities-names-top-biotech-stock-amid-sector-rally-65a732f8b3124bfcPharmaRadar360en2026-09-22T10:56:47.000ZBofA Securities Names Top Biotech Stock Amid Sector Rallyhttps://www.pharmaradar360.com/article/a-merck-drug-cut-the-risk-of-worsening-disease-by-76-the-fda-updated-its-label-35639d1ef2653d3ePharmaRadar360en2026-09-22T10:50:31.000ZA Merck drug cut the risk of worsening disease by 76%. The FDA updated its label.https://www.pharmaradar360.com/article/us-phenylephrine-hydrochloride-prices-hold-firm-as-q4-pharmaceutical-demand-stre-0149dcbbdb4b1dc3PharmaRadar360en2026-09-22T10:46:07.000ZUS Phenylephrine Hydrochloride Prices Hold Firm as Q4 Pharmaceutical Demand Strengthenshttps://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-d63bea0d0db63aa3PharmaRadar360en2026-09-22T10:45:00.000ZU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)https://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-68a2c21adf64b7b1PharmaRadar360en2026-09-22T10:42:26.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f39731160de90db0PharmaRadar360en2026-09-22T10:37:24.000ZThe Drugs And Devices Have Been On The Market For Years. But FDA-Ordered Studies Still Aren't Done.https://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-survey-a86c0a5b77beeed2PharmaRadar360en2026-09-22T10:00:05.000ZBeyond ADMET: AI for medicines safety - surveyhttps://www.pharmaradar360.com/article/harmoni-gi1-a-phase-iii-trial-featuring-ivonescimab-plus-chemotherapy-compared-t-5397d986a24a195aPharmaRadar360en2026-09-22T10:00:00.000ZHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMhttps://www.pharmaradar360.com/article/direct-nitrite-analysis-simplifies-tests-of-pharmaceutical-excipients-for-risk-c-4b362d430ed610eaPharmaRadar360en2026-09-22T10:00:00.000ZDirect nitrite analysis simplifies tests of pharmaceutical excipients for risk checkshttps://www.pharmaradar360.com/article/regulatory-round-up-22-september-2026-5ba9abe7a8a91f88PharmaRadar360en2026-09-22T09:23:41.000ZRegulatory round-up: 22 September 2026https://www.pharmaradar360.com/article/mannkind-corporation-mnkd-stock-analysis-exploring-a-127-68-potential-upside-in-88d42183e45cec68PharmaRadar360en2026-09-22T09:21:38.000ZMannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Spacehttps://www.pharmaradar360.com/article/book-review-the-age-of-cures-by-barry-werth-50b9ec628976b5a2PharmaRadar360en2026-09-22T09:00:43.000ZBook Review: ‘The Age of Cures,’ by Barry Werthhttps://www.pharmaradar360.com/article/boryung-signs-277-mil-taxotere-supply-deal-with-china-s-yifan-6f397d63d69e2dafPharmaRadar360en2026-09-22T08:37:41.000ZBoryung signs $277 mil. Taxotere supply deal with China’s Yifanhttps://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-director-pdmr-shareholding-bb695b3e1242f838PharmaRadar360en2026-09-22T08:32:40.000ZREG - Hikma Pharmaceutical - Director/PDMR Shareholdinghttps://www.pharmaradar360.com/article/ukhsa-and-university-of-oxford-scientists-uncover-genetic-changes-in-the-bacteri-619305ae10369373PharmaRadar360en2026-09-22T08:30:02.000ZUKHSA and University of Oxford scientists uncover genetic changes in the bacteria causing severe Kent meningococcal disease outbreakhttps://www.pharmaradar360.com/article/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2026-1002643f3a56701ePharmaRadar360en2026-09-22T08:30:01.000ZVoluntary scheme aggregate net sales and payment information: August 2026https://www.pharmaradar360.com/article/the-health-impacts-from-industrial-sources-of-pfas-a-rapid-review-ed4c661ce7265e41PharmaRadar360en2026-09-22T08:30:01.000ZThe health impacts from industrial sources of PFAS: a rapid reviewhttps://www.pharmaradar360.com/article/per-and-polyfluoroalkyl-substances-pfas-general-information-49da969af76edf3bPharmaRadar360en2026-09-22T08:30:01.000ZPer- and polyfluoroalkyl substances (PFAS): general informationhttps://www.pharmaradar360.com/article/vpag-quarterly-net-sales-and-payment-information-e87d48f3b7220662PharmaRadar360en2026-09-22T08:30:01.000ZVPAG quarterly net sales and payment informationhttps://www.pharmaradar360.com/article/chemical-hazards-compendium-2cf1a7b32dba1e24PharmaRadar360en2026-09-22T08:30:01.000ZChemical hazards compendiumhttps://www.pharmaradar360.com/article/hanyang-precision-chairman-countersues-former-hanmi-pharmaceutical-executives-29f8aa0fd33812f7PharmaRadar360en2026-09-22T08:20:49.000ZHanyang Precision Chairman Countersues Former Hanmi Pharmaceutical Executiveshttps://www.pharmaradar360.com/article/submicron-ir-for-pharmaceutical-research-development-and-quality-f91eaac67fdb6ecbPharmaRadar360en2026-09-22T07:44:00.000ZSubmicron IR for pharmaceutical research, development, and qualityhttps://www.pharmaradar360.com/article/sant-98561788d726bcd6PharmaRadar360en2026-09-22T07:40:28.000ZΕπίσκεψη αντιπροσωπείας της Επιτροπής Δημόσιας Υγείας (SANT) του Ευρωπαϊκού Κοινοβουλίου στον Εθνικό Οργανισμό Φαρμάκων (ΕΟΦ)https://www.pharmaradar360.com/article/fda-s-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sp-db564c899dadd3aaPharmaRadar360en2026-09-22T07:35:24.000ZFDA’s 2026 Single-Trial Default Standard Reframes the Dual-Pivotal Debate for Sponsors Still Designing Phase 3https://www.pharmaradar360.com/article/greece-to-prioritise-biosimilars-legislation-during-2027-eu-presidency-says-mini-7c952cb632ab6e86PharmaRadar360en2026-09-22T07:33:46.000ZGreece to prioritise biosimilars legislation during 2027 EU presidency, says ministerhttps://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-c8c0fec7c979c997PharmaRadar360en2026-09-22T07:28:01.000ZMayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offering.https://www.pharmaradar360.com/article/iambic-maintains-momentum-from-string-of-big-pharma-partnerships-by-aiming-for-i-14246701c70fe37fPharmaRadar360en2026-09-22T07:14:45.000ZIambic maintains momentum from string of Big Pharma partnerships by aiming for IPOhttps://www.pharmaradar360.com/article/trevi-therapeutics-stock-trades-at-usd-14-71-as-biotech-data-matters-663f1d5418a1fc34PharmaRadar360en2026-09-22T07:13:21.000ZTrevi Therapeutics stock trades at USD 14.71 as biotech data mattershttps://www.pharmaradar360.com/article/how-aspen-s-priyen-naidu-drives-a-human-centred-approach-to-technology-f2ab4450d8792b6aPharmaRadar360en2026-09-22T07:10:56.000ZHow Aspen’s Priyen Naidu drives a human-centred approach to technologyhttps://www.pharmaradar360.com/article/bank-of-america-corp-de-invests-38-35-million-in-ultragenyx-pharmaceutical-inc-r-127cbc20e446c4bfPharmaRadar360en2026-09-22T07:10:01.000ZBank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RAREhttps://www.pharmaradar360.com/article/building-on-success-ipsen-receives-two-new-gold-brandon-hall-awards-d9486765e1c17bb8PharmaRadar360en2026-09-22T07:00:00.000ZBuilding on Success: Ipsen Receives Two New Gold Brandon Hall Awardshttps://www.pharmaradar360.com/article/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimer-s-045429441a897961PharmaRadar360en2026-09-22T06:45:18.000ZMerry Life Biomedical Starts Phase 2 Trial of TML-6 for Early Alzheimer’shttps://www.pharmaradar360.com/article/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia-ae296af74503e57aPharmaRadar360en2026-09-22T06:40:39.000ZEC Approves Obicetrapib as Oral CETP Inhibitor for Hypercholesterolemiahttps://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411PharmaRadar360en2026-09-22T06:05:05.000ZBeyond clinical endpoints: Rethinking ALS drug development through disease biologyhttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-cadbbf2157ab9b29PharmaRadar360en2026-09-22T06:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritishttps://www.pharmaradar360.com/article/india-s-biotech-self-reliance-moment-102921bdf8bc7232PharmaRadar360en2026-09-22T05:50:11.000ZIndia’s biotech self-reliance momenthttps://www.pharmaradar360.com/article/5-best-glp-1-stocks-for-2026-and-how-to-invest-99408731658b95c2PharmaRadar360en2026-09-22T05:10:00.000Z5 Best GLP-1 Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/boryung-scores-277m-anti-cancer-drug-supply-deal-in-china-d65692bc15e5f4fcPharmaRadar360en2026-09-22T05:02:48.000ZBoryung scores $277m anti-cancer drug supply deal in Chinahttps://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-resu-ca3349841e8c60a5PharmaRadar360en2026-09-22T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityhttps://www.pharmaradar360.com/article/healthnet-mea-to-commercialise-comide-er-methylphenidate-er-in-uae-under-exclusi-25f7252f14d192bdPharmaRadar360en2026-09-22T05:00:00.000ZHealthNet MEA to Commercialise COMIDE ER® (Methylphenidate ER) in UAE Under Exclusive Agreement with Anxo Pharmaceuticalhttps://www.pharmaradar360.com/article/child-resistant-locking-closures-market-to-2035-pharmaceutical-safety-mandates-d-ee831d2ecb1081b6PharmaRadar360en2026-09-22T04:46:21.000ZChild-Resistant Locking Closures Market To 2035: Pharmaceutical Safety Mandates Drive Growth - News and Statisticshttps://www.pharmaradar360.com/article/india-news-96d7107e3a341182PharmaRadar360en2026-09-22T04:26:23.000ZIndia Newshttps://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-478bd63e265078d4PharmaRadar360en2026-09-22T03:35:46.000ZNvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls onhttps://www.pharmaradar360.com/article/us-fda-moves-away-from-animal-testing-how-organoids-ai-organs-on-chips-could-imp-8ae12dc92c9fbd34PharmaRadar360en2026-09-22T03:30:00.000ZUS FDA Moves Away From Animal Testing: How Organoids, AI & Organs-On-Chips Could Impact Drug Researchhttps://www.pharmaradar360.com/article/boryung-signs-277-million-taxotere-supply-deal-with-china-s-yifan-pharmaceutical-a71b4ed4f2241099PharmaRadar360en2026-09-22T03:05:00.000ZBoryung Signs $277 Million Taxotere Supply Deal with China's Yifan Pharmaceuticalhttps://www.pharmaradar360.com/article/melbourne-biotech-turns-to-stem-cell-brain-models-in-alzheimer-s-push-7ea3ae37b3c8e127PharmaRadar360en2026-09-22T02:35:55.000ZMelbourne biotech turns to stem cell brain models in Alzheimer's pushhttps://www.pharmaradar360.com/article/editorial-strict-checks-on-drug-supply-chain-9e99b919fddbd074PharmaRadar360en2026-09-22T02:29:02.000ZEditorial: Strict checks on drug supply chainhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524PharmaRadar360en2026-09-22T01:59:24.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/lilly-s-breast-cancer-combo-wins-approval-2625666fc10dfe92PharmaRadar360en2026-09-22T01:26:22.000ZLilly’s breast cancer combo wins approvalhttps://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-ultragenyx-pha-eb82ae5a7d95e0efPharmaRadar360en2026-09-22T01:26:00.000ZAnalysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-envista-holdin-90aff1940631b27aPharmaRadar360en2026-09-22T01:10:00.000ZAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)https://www.pharmaradar360.com/article/gc-wellbeing-and-boryung-expand-korea-hospital-use-of-livnec-injection-chosunbiz-f8357be306326357PharmaRadar360en2026-09-22T00:41:00.000ZGC Wellbeing and Boryung expand Korea hospital use of Livnec injection - CHOSUNBIZhttps://www.pharmaradar360.com/article/pfizer-details-phase-3-sleep-apnea-trial-for-ex-metsera-obesity-drug-9b66bc3b08304ba5PharmaRadar360en2026-09-22T00:38:54.000ZPfizer details phase 3 sleep apnea trial for ex-Metsera obesity drughttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-4fd90a4772882d47PharmaRadar360en2026-09-22T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-fd60ec54e19ca4ddPharmaRadar360en2026-09-22T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-ed2de6da22997440PharmaRadar360en2026-09-22T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-3e5f82e39c8b8bf4PharmaRadar360en2026-09-22T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f7927690eb466ad3PharmaRadar360en2026-09-22T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-a7ab313d50b6dd5cPharmaRadar360en2026-09-22T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a40a0eff36af50ddPharmaRadar360en2026-09-22T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-0aa0ed7c37800ffbPharmaRadar360en2026-09-22T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-4fa3fa5cb8800304PharmaRadar360en2026-09-22T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-98e36b23d5995f81PharmaRadar360en2026-09-22T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b18316af92c7180dPharmaRadar360en2026-09-22T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-92339e3d32b05f49PharmaRadar360en2026-09-22T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-9f39f62d36b861e7PharmaRadar360en2026-09-22T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-ec6a264c379d0165PharmaRadar360en2026-09-22T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-cancer-institute-notice-of-meeting-8918f24bc0866cb9PharmaRadar360en2026-09-22T00:00:00.000ZNational Cancer Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e3d513e458366039PharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-774090bba85bb2afPharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Questionnaire and Data Collection Testing, Evaluation, and Research for the Health Resources and Services Administration, OMB No. 0915-0379-Revisionhttps://www.pharmaradar360.com/article/nonclinical-testing-terminology-5eba25885ce1826aPharmaRadar360en2026-09-22T00:00:00.000ZNonclinical Testing Terminologyhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-c3c6da23622a87aePharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Generic Information Collection Request for Health Resources and Services Administration Hotlines, Chatlines, and Online Portalshttps://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-the-impact-and-costs-of-promoti-1981b0d77e209b56PharmaRadar360en2026-09-22T00:00:00.000ZSubmission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-ed0ae1132b37b44cPharmaRadar360en2026-09-22T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-request-fo-9ec32231184cff8dPharmaRadar360en2026-09-22T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Meeting; Request for Public Inputhttps://www.pharmaradar360.com/article/summary-for-patients-tobacco-use-treatment-synopsis-of-the-2026-u-s-department-o-07d3fe471f477728PharmaRadar360en2026-09-22T00:00:00.000ZSummary for Patients: Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelinehttps://www.pharmaradar360.com/article/hybrid-endoscopic-submucosal-dissection-enhances-efficiency-with-comparable-cura-59f35ebeba6339bcPharmaRadar360en2026-09-22T00:00:00.000ZHybrid endoscopic submucosal dissection enhances efficiency with comparable curative outcomes: a Bayesian meta-analysis, systematic review, and Monte Carlo simulation of randomized controlled trialshttps://www.pharmaradar360.com/article/advances-risks-and-implementation-challenges-of-artificial-intelligence-as-a-for-0aaebc5fc67cb1f4PharmaRadar360en2026-09-22T00:00:00.000ZAdvances, Risks, And Implementation Challenges of Artificial Intelligence as A Force Multiplier for Clinical Decision Making and Health System Efficiencyhttps://www.pharmaradar360.com/article/to-what-extent-is-water-hydration-the-best-method-of-maintaining-voice-protectio-c0b14f3feb98d6fcPharmaRadar360en2026-09-22T00:00:00.000ZTo what extent is water hydration the best method of maintaining voice protection among frequent voice users?https://www.pharmaradar360.com/article/design-and-limitations-of-tumor-microenvironment-responsive-nanocarriers-for-tar-a541e35ac2a228ebPharmaRadar360en2026-09-22T00:00:00.000ZDesign and Limitations of Tumor Microenvironment-Responsive Nanocarriers for Targeted Drug Deliveryhttps://www.pharmaradar360.com/article/ethical-legal-and-societal-implications-in-xenotransplantation-elsi-a-korean-reg-574b7c8e38dc1ea4PharmaRadar360en2026-09-22T00:00:00.000ZEthical, legal, and societal implications in xenotransplantation (ELSI): a Korean regulatory perspectivehttps://www.pharmaradar360.com/article/practicing-in-resource-limited-and-siloed-settings-b8a360d6cc716831PharmaRadar360en2026-09-22T00:00:00.000ZPracticing in Resource-Limited and Siloed Settingshttps://www.pharmaradar360.com/article/synbiotic-hqp08-supplementation-for-hair-loss-and-depressive-symptoms-an-open-la-d810c0348c9d2a53PharmaRadar360en2026-09-22T00:00:00.000ZSynbiotic HQP08 Supplementation for Hair Loss and Depressive Symptoms: An Open-Label Pilot Study of Clinical Outcomes and Gut Microbiome Changeshttps://www.pharmaradar360.com/article/effectiveness-of-participatory-strategies-for-prevention-of-dengue-and-leptospir-8b622e47d75a3a2ePharmaRadar360en2026-09-22T00:00:00.000ZEffectiveness of Participatory Strategies for Prevention of Dengue and Leptospirosis: A Two-Year Controlled Community Trial in Santa Fe, Argentinahttps://www.pharmaradar360.com/article/early-cardiotoxicity-in-pediatric-patients-with-acute-lymphoblastic-leukemia-and-66bd0483b1ad137dPharmaRadar360en2026-09-22T00:00:00.000ZEarly Cardiotoxicity in Pediatric Patients with Acute Lymphoblastic Leukemia and Hodgkin Lymphoma: Incidence, Risk Factors, and Clinical Implicationshttps://www.pharmaradar360.com/article/integrating-tumour-biology-into-surgical-decision-making-for-metastatic-colorect-72069f85a27f2b65PharmaRadar360en2026-09-22T00:00:00.000ZIntegrating Tumour Biology into Surgical Decision-Making for Metastatic Colorectal Cancer: A Real-World Cohort Analysis Adapted for Clinical Colorectal Cancerhttps://www.pharmaradar360.com/article/asparagine-synthetase-deficiency-a-novel-asns-variant-and-a-systematic-review-of-7688496f64879380PharmaRadar360en2026-09-22T00:00:00.000ZAsparagine Synthetase Deficiency: A Novel ASNS Variant and a Systematic Review of Clinical Phenotypes and Cerebrospinal Fluid Asparagine Levelshttps://www.pharmaradar360.com/article/economic-evaluation-of-primary-health-care-integration-and-targeted-mass-drug-ad-23f6f417faae079ePharmaRadar360en2026-09-22T00:00:00.000ZEconomic evaluation of primary health care integration and targeted mass drug administration in counties in western Kenyahttps://www.pharmaradar360.com/article/clinical-outcomes-following-a-traditional-chinese-medicine-foot-bath-preparation-71dccefa5ac0c66ePharmaRadar360en2026-09-22T00:00:00.000ZClinical outcomes following a traditional Chinese medicine foot bath preparation for lower-limb edema and sleep disturbance: a single-center retrospective study of 2,000 patientshttps://www.pharmaradar360.com/article/association-between-post-procedural-parenteral-anticoagulation-therapy-and-clini-aa105c9902a1b506PharmaRadar360en2026-09-22T00:00:00.000ZAssociation between post procedural parenteral anticoagulation therapy and clinical outcomes in ST-elevation myocardial infarction patients with high thrombotic riskhttps://www.pharmaradar360.com/article/thromboembolic-prophylaxis-in-childhood-idiopathic-nephrotic-syndrome-from-patho-561cd01380060c71PharmaRadar360en2026-09-22T00:00:00.000ZThromboembolic prophylaxis in childhood idiopathic nephrotic syndrome. From pathophysiology to clinical managementhttps://www.pharmaradar360.com/article/ultrasound-defined-fatty-liver-and-the-risk-of-progression-from-preclinical-to-c-f9a84b6d726a3f6ePharmaRadar360en2026-09-22T00:00:00.000ZUltrasound-defined fatty liver and the risk of progression from preclinical to clinical obesity: a prospective cohort studyhttps://www.pharmaradar360.com/article/hematoma-expansion-in-intracerebral-hemorrhage-neuroimaging-biomarkers-radiomics-e09c758c16081ca4PharmaRadar360en2026-09-22T00:00:00.000ZHematoma expansion in intracerebral hemorrhage: neuroimaging biomarkers, radiomics-based prediction models, and clinical translationhttps://www.pharmaradar360.com/article/editorial-non-invasive-brain-stimulation-from-basic-science-to-clinical-applicat-57c6e566091c722cPharmaRadar360en2026-09-22T00:00:00.000ZEditorial: Non-invasive brain stimulation: from basic science to clinical applicationhttps://www.pharmaradar360.com/article/from-fracture-stabilization-to-functional-recovery-a-prospective-clinical-radiol-b0de384d30fed29fPharmaRadar360en2026-09-22T00:00:00.000ZFrom Fracture Stabilization to Functional Recovery: A Prospective Clinical–Radiological Study of Hybrid External Fixation in Schatzker V and VI Tibial Plateau Fractureshttps://www.pharmaradar360.com/article/clinical-and-radiological-outcomes-after-philos-locking-plate-fixa-tion-of-proxi-6cb1d9db4ee8d196PharmaRadar360en2026-09-22T00:00:00.000ZClinical and Radiological Outcomes After PHILOS Locking-Plate Fixa-tion of Proximal Humeral Fractures: A Prospective Observational Study from a Tertiary Care Centre in South Indiahttps://www.pharmaradar360.com/article/magnetic-resonance-imaging-evaluation-of-oblique-injuries-introduction-of-the-de-8fc08014efbffe9ePharmaRadar360en2026-09-22T00:00:00.000ZMagnetic resonance imaging evaluation of oblique injuries: Introduction of the deadrise signhttps://www.pharmaradar360.com/article/a-reproducible-framework-for-auditing-the-trustworthiness-of-clinical-machine-le-e156ce2fb89f21bePharmaRadar360en2026-09-22T00:00:00.000ZA Reproducible Framework for Auditing the Trustworthiness of Clinical Machine Learning Modelshttps://www.pharmaradar360.com/article/beyond-statistical-similarity-a-clinical-validation-framework-for-synthetic-acut-72e3848e5ab24c81PharmaRadar360en2026-09-22T00:00:00.000ZBeyond Statistical Similarity: A Clinical Validation Framework for Synthetic Acute Myeloid Leukemia Cohorts Run head title: Clinical Validation of Synthetic AML Datahttps://www.pharmaradar360.com/article/the-association-between-clinical-activity-and-inflammatory-response-in-odontogen-bd41993f007c7d9aPharmaRadar360en2026-09-22T00:00:00.000ZThe association between clinical activity and inflammatory response in odontogenic keratocysts. A retrospective studyhttps://www.pharmaradar360.com/article/effects-of-lean-beef-on-resistance-training-induced-strength-and-body-compositio-7dbccd69d52aea28PharmaRadar360en2026-09-22T00:00:00.000ZEffects of lean beef on resistance training-induced strength and body composition adaptations: a randomized controlled trial protocol.https://www.pharmaradar360.com/article/antioxidant-premedication-reduces-mitochondrial-and-nuclear-dna-damage-repair-in-cecfc8008ef47d6fPharmaRadar360en2026-09-22T00:00:00.000ZAntioxidant premedication reduces mitochondrial and nuclear DNA damage repair in interventional physicians performing X-ray-guided angiography procedures: a pilot clinical intervention studyhttps://www.pharmaradar360.com/article/ct-derived-myocardial-extracellular-volume-current-evidence-clinical-utility-and-f91615e1f0f6a045PharmaRadar360en2026-09-22T00:00:00.000ZCT-derived myocardial extracellular volume: current evidence, clinical utility, and the emerging role of photon-counting CT—a systematic reviewhttps://www.pharmaradar360.com/article/early-phosphate-supplementation-after-newly-detected-hypophosphatemia-in-older-i-5ee50f7a22451580PharmaRadar360en2026-09-22T00:00:00.000ZEarly phosphate supplementation after newly detected hypophosphatemia in older ICU patients: a target trial emulationhttps://www.pharmaradar360.com/article/associations-between-social-determinants-of-health-and-clinical-diagnosis-time-o-ba252f64579ea133PharmaRadar360en2026-09-22T00:00:00.000ZAssociations between social determinants of health and clinical diagnosis time of uterine fibroids and endometriosis: a cross-sectional electronic health record-based studyhttps://www.pharmaradar360.com/article/the-stroke-crisis-in-ageing-societies-global-trends-risk-factors-and-clinical-va-eebc145ad0ea6beaPharmaRadar360en2026-09-22T00:00:00.000ZThe stroke crisis in ageing societies: global trends, risk factors, and clinical validationhttps://www.pharmaradar360.com/article/response-by-maurer-and-fontana-to-letter-regarding-article-coramitug-a-humanized-b092e4d1b40d77b4PharmaRadar360en2026-09-22T00:00:00.000ZResponse by Maurer and Fontana to Letter Regarding Article, “Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial”https://www.pharmaradar360.com/article/comparison-of-3-dual-single-pill-combinations-for-blood-pressure-lowering-a-seco-934d9095d9196874PharmaRadar360en2026-09-22T00:00:00.000ZComparison of 3 Dual Single-Pill Combinations for Blood Pressure Lowering: A Secondary Analysis of an International Randomized Trialhttps://www.pharmaradar360.com/article/psychological-pathways-from-disease-activity-to-quality-of-life-in-ulcerative-co-0133cc63b78f7bb5PharmaRadar360en2026-09-22T00:00:00.000ZPsychological Pathways From Disease Activity to Quality of Life in Ulcerative Colitis and Crohn's Disease: A Cross‐Sectional Serial Mediation Studyhttps://www.pharmaradar360.com/article/my-unbearable-wife-gave-me-a-brain-tumor-subjective-theories-of-illness-and-reco-d9c4caf1f4a588e9PharmaRadar360en2026-09-22T00:00:00.000Z‘My Unbearable Wife Gave Me a Brain Tumor:’ Subjective Theories of Illness and Recovery in Robert Miller’s Yoga-Centered Healing Narrativehttps://www.pharmaradar360.com/article/when-therapists-need-to-be-their-own-clients-the-influence-of-intersectional-pri-12d08479260be075PharmaRadar360en2026-09-22T00:00:00.000ZWhen Therapists Need to Be Their Own Clients: The Influence of Intersectional Privilege and Discrimination on Therapy and the Need to Talk About It Through Therapeutic Self-Disclosurehttps://www.pharmaradar360.com/article/contributions-of-semiotic-cultural-psychology-for-interventions-in-clinical-psyc-cf12230181a710fbPharmaRadar360en2026-09-22T00:00:00.000ZContributions of Semiotic Cultural Psychology for Interventions in Clinical Psychologyhttps://www.pharmaradar360.com/article/health-literacy-antibiotic-use-behaviors-and-awareness-of-antimicrobial-resistan-7a7abb1fc6fe4ec9PharmaRadar360en2026-09-22T00:00:00.000ZHealth Literacy, Antibiotic Use Behaviors, and Awareness of Antimicrobial Resistance Among Patients in Karachi, Pakistanhttps://www.pharmaradar360.com/article/clinical-impact-of-introducing-automated-plan-checking-in-radiation-therapy-effe-220fbd73db8233f8PharmaRadar360en2026-09-22T00:00:00.000ZClinical impact of introducing automated plan checking in radiation therapy: effects on workflow efficiency, cognitive load and usabilityhttps://www.pharmaradar360.com/article/comment-on-effectiveness-safety-and-tolerability-of-ozenoxacin-2-lotion-vs-clind-75efa1fd26813f4cPharmaRadar360en2026-09-22T00:00:00.000ZComment on ‘Effectiveness, safety and tolerability of ozenoxacin 2% lotion vs clindamycin 1% lotion in mild to moderate truncal acne’: considerations regarding sample size and treatment-related withdrawalhttps://www.pharmaradar360.com/article/bacterial-outer-membrane-vesicles-in-colorectal-cancer-interdomain-communication-95e0d6534503eb25PharmaRadar360en2026-09-22T00:00:00.000ZBacterial outer membrane vesicles in colorectal cancer: interdomain communication hubs in pathogenesis and immunotherapyhttps://www.pharmaradar360.com/article/association-between-early-systolic-blood-pressure-and-clinical-outcomes-in-non-c-69ae09590efea90ePharmaRadar360en2026-09-22T00:00:00.000ZAssociation between early systolic blood pressure and clinical outcomes in non-critically ill patients with sepsis-associated acute kidney injury: a retrospective cohort studyhttps://www.pharmaradar360.com/article/efficacy-of-combined-repetitive-transcranial-magnetic-stimulation-and-occupation-b74d503d8324ad1ePharmaRadar360en2026-09-22T00:00:00.000ZEfficacy of combined repetitive transcranial magnetic stimulation and occupational therapy in spinal cord injury patients: a randomized controlled clinical studyhttps://www.pharmaradar360.com/article/pharmacovigilance-practices-educational-interventions-and-barriers-to-reporting-535468794e77582dPharmaRadar360en2026-09-22T00:00:00.000ZPharmacovigilance Practices, Educational Interventions and Barriers to Reporting in University and Teaching Hospitals: a Scoping Reviewhttps://www.pharmaradar360.com/article/occupational-allergies-clinical-presentation-epidemiology-diagnosis-and-preventi-d3e45acd9d403f28PharmaRadar360en2026-09-22T00:00:00.000ZOccupational allergies—clinical presentation, epidemiology, diagnosis, and preventionhttps://www.pharmaradar360.com/article/development-of-a-conceptual-disease-model-of-atopic-dermatitis-using-data-from-t-b724371d717c237fPharmaRadar360en2026-09-22T00:00:00.000ZDevelopment of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 Trialhttps://www.pharmaradar360.com/article/anti-tnf-refractory-inflammatory-bowel-disease-associated-with-a-novel-xiap-fram-b48dd066032a9779PharmaRadar360en2026-09-22T00:00:00.000ZAnti-TNF–refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumabhttps://www.pharmaradar360.com/article/effect-of-cuprous-oxide-nanoparticles-green-synthesized-using-artemisia-dracuncu-cc51fb0cd6ece9b8PharmaRadar360en2026-09-22T00:00:00.000ZEffect of Cuprous Oxide Nanoparticles Green-synthesized Using Artemisia dracunculus Extract on Cell-cycle Progression and Apoptosis in Bladder Cancer Cellshttps://www.pharmaradar360.com/article/development-and-evaluation-of-a-hydroxyurea-loaded-invasome-hydrogel-for-enhance-994c6bdc360fa4ccPharmaRadar360en2026-09-22T00:00:00.000ZDevelopment and Evaluation of a Hydroxyurea-loaded Invasome Hydrogel for Enhanced Anti-psoriatic Efficacy and Reduced Systemic Exposurehttps://www.pharmaradar360.com/article/photocatalytic-treatment-of-organic-and-pharmaceutical-pollutants-in-wastewater-fb6ba995d39dc801PharmaRadar360en2026-09-22T00:00:00.000ZPhotocatalytic treatment of organic and pharmaceutical pollutants in wastewater using Ni-doped TiO2 nanoparticleshttps://www.pharmaradar360.com/article/tissue-specific-aging-clocks-map-structured-aging-modulatory-drug-score-patterns-9b721b6fd4c871b6PharmaRadar360en2026-09-22T00:00:00.000ZTissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categorieshttps://www.pharmaradar360.com/article/diagnostic-accuracy-amp-clinical-importance-of-ai-confidence-for-extremity-fract-cf31f9fe3c4a8ca6PharmaRadar360en2026-09-22T00:00:00.000ZDiagnostic accuracy &amp; clinical importance of AI confidence for extremity fracture detection: 2,508-patient retrospective cohorthttps://www.pharmaradar360.com/article/could-previous-appendicectomy-influence-disease-expression-in-axial-spondyloarth-e9e0c066f4387e8fPharmaRadar360en2026-09-22T00:00:00.000ZCould previous appendicectomy influence disease expression in axial spondyloarthritis?https://www.pharmaradar360.com/article/clinical-performance-of-glass-hybrid-and-short-fiber-reinforced-composite-restor-651b546e41d9bbe2PharmaRadar360en2026-09-22T00:00:00.000ZClinical performance of glass hybrid and short fiber-reinforced composite restorations in MIH-affected molars: A 60-month split-mouth randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-interchangeability-of-22c3-and-28-8-pd-l1-assays-for-patient-selection-343e8ac84fe0cb4fPharmaRadar360en2026-09-22T00:00:00.000ZClinical Interchangeability of 22C3 and 28 − 8 PD-L1 assays for patient selection in esophageal squamous cell carcinomahttps://www.pharmaradar360.com/article/glaucoma-in-hospitalized-older-adults-polypharmacy-multimorbidity-and-therapy-di-fbced7d96caeaf15PharmaRadar360en2026-09-22T00:00:00.000ZGlaucoma in hospitalized older adults: polypharmacy, multimorbidity, and therapy discontinuation – a REPOSI registry analysishttps://www.pharmaradar360.com/article/specific-treatment-of-attr-cm-in-germany-expert-consensus-of-the-german-society-4b5e24406ecb15a6PharmaRadar360en2026-09-22T00:00:00.000ZSpecific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)https://www.pharmaradar360.com/article/regimen-stratified-bayesian-model-based-meta-analysis-of-targeted-biologics-in-g-760b3481681182f4PharmaRadar360en2026-09-22T00:00:00.000ZRegimen-stratified Bayesian model-based meta-analysis of targeted biologics in generalised myasthenia gravis: efficacy comparison, mechanism-level class contrast, and endpoint sensitivity with model-informed trial designhttps://www.pharmaradar360.com/article/measuring-what-vlms-don-t-say-validation-metrics-hide-clinical-terminology-erasu-ad6cc70c31430f76PharmaRadar360en2026-09-22T00:00:00.000ZMeasuring What VLMs Don’t Say: Validation Metrics Hide Clinical Terminology Erasure in Radiology Report Generationhttps://www.pharmaradar360.com/article/circulating-blood-biomarkers-after-traumatic-brain-injury-a-subanalysis-of-the-b-62e62e5a6d913481PharmaRadar360en2026-09-22T00:00:00.000ZCirculating blood biomarkers after traumatic brain injury: A subanalysis of the biperiden phase <scp>III</scp> randomized, double‐blind clinical trial ( <scp>NCT01048138</scp> )https://www.pharmaradar360.com/article/amcham-imss-deal-pledges-us-44-million-to-bring-clinical-trials-to-mexican-publi-052095dbcfb7da9aPharmaRadar360en2026-09-21T23:39:40.000ZAmCham-IMSS deal pledges US $44 million to bring clinical trials to Mexican public hospitalshttps://www.pharmaradar360.com/article/nice-recommends-enhertu-for-her2-low-advanced-breast-cancer-in-england-9d334852ef112a45PharmaRadar360en2026-09-21T22:50:26.000ZNICE recommends Enhertu for HER2-low advanced breast cancer in Englandhttps://www.pharmaradar360.com/article/drummond-warns-rubio-of-national-security-risk-in-pharmaceutical-supply-chain-5a65cb2ace796337PharmaRadar360en2026-09-21T22:48:21.000ZDrummond warns Rubio of national security risk in pharmaceutical supply chainhttps://www.pharmaradar360.com/article/u-s-rulemaking-chatter-lifts-hong-kong-s-china-biotech-names-4fcfe264207382d9PharmaRadar360en2026-09-21T22:12:00.000ZU.S. rulemaking chatter lifts Hong Kong's China biotech nameshttps://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-6bcac29ff06fe76bPharmaRadar360en2026-09-21T21:41:00.000ZNvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls onhttps://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776PharmaRadar360en2026-09-21T21:41:00.000ZPharmaceutical Companies Push Trump Administration to Protect China Dealshttps://www.pharmaradar360.com/article/pharmaceutical-logistics-market-to-reach-usd-194-0-billion-by-2034-at-7-7-cagr-d-405b29a18e79aec5PharmaRadar360en2026-09-21T21:30:00.000ZPharmaceutical Logistics Market to Reach USD 194.0 Billion by 2034 at 7.7% CAGR, Driven by Rising Demand for Cold-Chain Logistics and Digital Supply Chain Solutions, Says Maximize Market Researchhttps://www.pharmaradar360.com/article/biotech-stocks-and-leveraged-etfs-lead-market-d-9c02833c76771b58PharmaRadar360en2026-09-21T21:28:06.000ZBiotech stocks and leveraged ETFs lead market d...https://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-plant-078eb0965183eec9PharmaRadar360en2026-09-21T21:21:24.000ZEli Lilly breaks ground on $6.5B Houston planthttps://www.pharmaradar360.com/article/dompe-settlement-highlights-doj-continued-scrutiny-of-pharmaceutical-manufacture-433de672942d089bPharmaRadar360en2026-09-21T21:15:52.000ZDompe Settlement Highlights DOJ Continued Scrutiny of Pharmaceutical Manufacturer Donationshttps://www.pharmaradar360.com/article/iam-ipo-news-small-molecule-biotech-iambic-therapeutics-files-for-a-100-million-3bc12612e27dfbeePharmaRadar360en2026-09-21T21:10:00.000ZIAM IPO News - Small molecule biotech Iambic Therapeutics files for a $100 million IPOhttps://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-pharmaceutical-factory-in-houston-2f381a479b3555a2PharmaRadar360en2026-09-21T20:58:07.000ZEli Lilly breaks ground on $6.5B pharmaceutical factory in Houstonhttps://www.pharmaradar360.com/article/screening-china-origin-biotech-ip-a-new-u-s-eu-divide-fe79769761ea8dd8PharmaRadar360en2026-09-21T20:45:14.000ZScreening China-Origin Biotech IP: A New U.S.-EU Dividehttps://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-4b5e30b480cbde92PharmaRadar360en2026-09-21T20:38:12.000ZNvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls onhttps://www.pharmaradar360.com/article/medicus-pfizer-deal-was-not-a-fire-sale-a-strategic-bet-on-de-risked-adc-drug-8e03cd57f1797c93PharmaRadar360en2026-09-21T20:35:01.000ZMedicus Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drughttps://www.pharmaradar360.com/article/buerger-s-disease-clinical-trial-pipeline-gains-momentum-3-91e1bc0bbb6b2beaPharmaRadar360en2026-09-21T20:24:04.000ZBuerger's Disease Clinical Trial Pipeline Gains Momentum: 3+https://www.pharmaradar360.com/article/the-glp-1-shortage-is-over-mass-market-compounding-should-be-too-5d8cd6869a85189bPharmaRadar360en2026-09-21T20:06:50.000ZThe GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Toohttps://www.pharmaradar360.com/article/eli-lilly-connected-peninsula-company-plots-ipo-as-it-takes-on-eczema-and-more-0871b8e09373ffcePharmaRadar360en2026-09-21T19:51:00.000ZEli Lilly-connected Peninsula company plots IPO as it takes on eczema and morehttps://www.pharmaradar360.com/article/par-health-issues-voluntary-nationwide-recall-of-two-lots-of-dexmedetomidine-hcl-488b45799ea71d6aPharmaRadar360en2026-09-21T19:37:58.000ZPar Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection Due to the Presence of Particulate Matterhttps://www.pharmaradar360.com/article/positive-topline-phase-3-study-results-lumateperone-for-manic-episodes-in-bipola-ea5127591948df34PharmaRadar360en2026-09-21T19:34:05.000ZPositive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorderhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-why-is-it-back-in-the-spotlight-feca7b108b11fdafPharmaRadar360en2026-09-21T19:11:35.000ZTeva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight?https://www.pharmaradar360.com/article/cphi-milan-leadership-summit-returns-with-supply-chain-focus-543b72ef7ec0a6e6PharmaRadar360en2026-09-21T19:06:56.000ZCPHI Milan Leadership Summit Returns With Supply Chain Focushttps://www.pharmaradar360.com/article/faq-how-the-generous-model-applies-mfn-pricing-to-medicaid-3108639fbd284b85PharmaRadar360en2026-09-21T19:04:10.000ZFAQ: How the GENEROUS Model Applies MFN Pricing to Medicaidhttps://www.pharmaradar360.com/article/new-analyses-of-hlp003-for-the-adjunctive-treatment-of-mdd-610c32551287df6ePharmaRadar360en2026-09-21T19:04:04.000ZNew Analyses of HLP003 for the Adjunctive Treatment of MDDhttps://www.pharmaradar360.com/article/otsuka-icu-medical-llc-issues-voluntary-nationwide-recall-of-0-9-sodium-chloride-61a649d42d701917PharmaRadar360en2026-09-21T19:00:20.000ZOtsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injectionhttps://www.pharmaradar360.com/article/abbvie-forms-ai-powered-drug-discovery-partnership-with-iambic-pharmexec-7df1eac9f5ddbb27PharmaRadar360en2026-09-21T18:57:11.000ZAbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic | PharmExechttps://www.pharmaradar360.com/article/fda-updates-regulations-to-expand-alternatives-to-animal-testing-in-drug-develop-0ab1dcb84feb442aPharmaRadar360en2026-09-21T18:33:35.000ZFDA Updates Regulations to Expand Alternatives to Animal Testing in Drug Developmenthttps://www.pharmaradar360.com/article/s2s-china-selects-10-biotech-finalists-to-pitch-global-investors-at-westlake-uni-cc798694b80a8b1bPharmaRadar360en2026-09-21T18:33:09.000ZS2S China Selects 10 Biotech Finalists To Pitch Global Investors At Westlake Universityhttps://www.pharmaradar360.com/article/sec-fda-information-sharing-mou-implications-for-pharma-and-biotech-f12ad8cd85d5f095PharmaRadar360en2026-09-21T18:24:09.000ZSEC-FDA Information-Sharing MOU: Implications for Pharma and Biotechhttps://www.pharmaradar360.com/article/pharmosa-biopharm-s-inhaled-drug-l608-wins-fda-approval-for-phase-2-trial-shares-623a9af03fd0b72dPharmaRadar360en2026-09-21T18:23:00.000ZPharmosa Biopharm's Inhaled Drug L608 Wins FDA Approval for Phase 2 Trial; Shares Hit Daily Limit Up Intradayhttps://www.pharmaradar360.com/article/life-sciences-real-estate-trends-what-to-expect-3bd7b4d3a44b9c76PharmaRadar360en2026-09-21T18:05:08.000ZLife Sciences Real Estate Trends – What to Expecthttps://www.pharmaradar360.com/article/biotech-stocks-to-watch-and-pharma-industry-news-72f24107382921a8PharmaRadar360en2026-09-21T17:49:00.000ZBiotech Stocks To Watch And Pharma Industry Newshttps://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-innovative-alternatives-to-animal-testing-895b941874bc4068PharmaRadar360en2026-09-21T17:14:21.000ZFDA Updates Regulations to Advance Innovative Alternatives to Animal Testinghttps://www.pharmaradar360.com/article/drugs-racket-kingpin-s-pharmacy-stayed-open-after-raid-health-officer-suspended-710aba0a714d4a51PharmaRadar360en2026-09-21T17:14:00.000ZDrugs racket kingpin’s pharmacy stayed open after raid, health officer suspendedhttps://www.pharmaradar360.com/article/drug-developer-adarx-seeks-1-74-billion-valuation-in-us-ipo-da6c89fec62607a7PharmaRadar360en2026-09-21T16:55:20.000ZDrug developer ADARx seeks $1.74 billion valuation in US IPOhttps://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574PharmaRadar360en2026-09-21T16:20:17.000ZThis Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Yearhttps://www.pharmaradar360.com/article/xenetic-to-acquire-santersus-in-net-targeting-biotech-combination-ec88c0dae17857a4PharmaRadar360en2026-09-21T16:15:47.000ZXenetic to acquire Santersus in NET-targeting biotech combinationhttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-third-glutathione-recall-issued-over-endotoxin-contamin-07b548b075a272fePharmaRadar360en2026-09-21T16:12:16.000ZFDA Recalls and Warnings: Third Glutathione Recall Issued Over Endotoxin Contaminationhttps://www.pharmaradar360.com/article/biotech-etfs-to-buy-as-cancer-drug-breakthroughs-accelerate-bd41f997cae1257cPharmaRadar360en2026-09-21T16:03:00.000ZBiotech ETFs to Buy as Cancer Drug Breakthroughs Acceleratehttps://www.pharmaradar360.com/article/bengaluru-assistant-drug-controller-suspended-in-counterfeit-drug-case-3638b689e7e0c3d9PharmaRadar360en2026-09-21T15:50:21.000ZBengaluru: Assistant drug controller suspended in counterfeit drug casehttps://www.pharmaradar360.com/article/european-commission-approves-roche-s-susvimo-for-the-treatment-of-neovascular-ag-5503298c000d9a8aPharmaRadar360en2026-09-21T15:45:00.000ZEuropean Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)https://www.pharmaradar360.com/article/moderna-surges-9-as-phase-3-melanoma-data-wins-presidential-symposium-slot-merck-3da8f65777798006PharmaRadar360en2026-09-21T15:45:00.000ZModerna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higherhttps://www.pharmaradar360.com/article/one-of-my-top-small-cap-biotech-picks-made-a-move-here-s-how-i-trade-it-6eb55c5568c32d22PharmaRadar360en2026-09-21T15:15:00.000ZOne of My Top Small-Cap Biotech Picks Made a Move. Here’s How I Trade Ithttps://www.pharmaradar360.com/article/bmy-vs-gild-which-biotech-stock-looks-more-attractive-now-6c620882c75be90dPharmaRadar360en2026-09-21T15:08:19.000ZBMY vs GILD: Which Biotech Stock Looks More Attractive Now?https://www.pharmaradar360.com/article/the-top-7-atypical-psychedelics-a-brief-clinical-guide-3d93abb04fc90f32PharmaRadar360en2026-09-21T15:06:54.000ZThe Top 7 Atypical Psychedelics: A Brief Clinical Guidehttps://www.pharmaradar360.com/article/weekly-roundup-on-the-cannabis-sector-psychedelic-sector-a4229cf49083a849PharmaRadar360en2026-09-21T15:01:50.000ZWeekly Roundup on the Cannabis Sector & Psychedelic Sectorhttps://www.pharmaradar360.com/article/bytedance-baidu-hengrui-novo-nordisk-driving-breakthroughs-in-ai-pharmaceutical-fbcbc6c19d988c7cPharmaRadar360en2026-09-21T15:01:47.000ZByteDance, Baidu, Hengrui & Novo Nordisk: Driving Breakthroughs in AI Pharmaceutical Commercializationhttps://www.pharmaradar360.com/article/pharma-and-biotech-industry-audit-services-for-gmp-gxp-and-supplier-compliance-2ecc2a1cefcf64f8PharmaRadar360en2026-09-21T14:58:13.000ZPharma and biotech industry audit services for GMP, GxP and supplier compliancehttps://www.pharmaradar360.com/article/the-fda-wants-pro-life-states-to-keep-waiting-b6f6153c4948a5f2PharmaRadar360en2026-09-21T14:57:00.000ZThe FDA wants pro-life states to keep waitinghttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-sehk-1093-expands-its-pipeline-is-the-stock-still-unde-873fbda566f6532fPharmaRadar360en2026-09-21T14:52:31.000ZCSPC Pharmaceutical Group (SEHK:1093) Expands Its Pipeline, Is The Stock Still Undervalued?https://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-and-clinical-site-readiness-to-initiate-p-2dfc2ee296889841PharmaRadar360en2026-09-21T14:45:50.000ZLakewood-Amedex Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3https://www.pharmaradar360.com/article/plug-and-play-seattle-picks-11-startups-for-4th-cohort-from-space-robotics-to-bi-a4ef32ff512f3201PharmaRadar360en2026-09-21T14:42:18.000ZPlug and Play Seattle picks 11 startups for 4th cohort, from space robotics to biotechhttps://www.pharmaradar360.com/article/beijing-unveils-blueprint-for-biomedical-dominance-by-2030-d2e6d08e6ff0538cPharmaRadar360en2026-09-21T14:41:18.000ZBeijing unveils blueprint for biomedical dominance by 2030https://www.pharmaradar360.com/article/concord-biotech-bonus-issue-sparks-rally-pharma-stock-jumps-6-on-maiden-share-re-3ca3b429b4874d3ePharmaRadar360en2026-09-21T14:28:37.000ZConcord Biotech bonus issue sparks rally! Pharma stock jumps 6% on maiden share reward - Top things to knowhttps://www.pharmaradar360.com/article/evita-clinical-trial-evaluates-oral-vitamin-c-for-pre-cancerous-blood-disorders-8e446074c31c386ePharmaRadar360en2026-09-21T14:26:00.000ZEVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disordershttps://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-ac0ba1a6f705851fPharmaRadar360en2026-09-21T13:59:03.000ZSerbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Sciencehttps://www.pharmaradar360.com/article/fda-updates-regulations-to-advance-alternatives-to-animal-testing-efae5931c8e859cdPharmaRadar360en2026-09-21T13:45:39.000ZFDA updates regulations to advance alternatives to animal testinghttps://www.pharmaradar360.com/article/reunion-del-comite-de-medicamentos-veterinarios-de-septiembre-de-2026-224e8a08e13866caPharmaRadar360en2026-09-21T13:44:59.000ZReunión del Comité de Medicamentos Veterinarios de septiembre de 2026https://www.pharmaradar360.com/article/fda-cancels-16-drug-licences-suspended-08-others-in-connection-with-alleged-dist-51785b064dcf2dedPharmaRadar360en2026-09-21T13:35:55.000ZFDA cancels 16 drug licences & suspended 08 others in connection with alleged distribution/sale of spurious medicineshttps://www.pharmaradar360.com/article/eu-pharma-reform-strategic-implications-for-us-drugmakers-8f7f8ee4ad186bb7PharmaRadar360en2026-09-21T13:27:39.000ZEU Pharma Reform: Strategic Implications for US Drugmakershttps://www.pharmaradar360.com/article/china-targets-25-share-of-global-first-in-class-drugs-in-new-5-year-plan-0e7df4b725539007PharmaRadar360en2026-09-21T13:12:24.000ZChina targets 25% share of global first-in-class drugs in new 5-year planhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-stock-price-expected-to-rise-barclays-anal-81130dfa0ccc6837PharmaRadar360en2026-09-21T13:05:49.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Barclays Analyst Sayshttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7PharmaRadar360en2026-09-21T13:00:11.000ZWorking for DHSChttps://www.pharmaradar360.com/article/two-new-cholesterol-drugs-get-their-first-global-approval-in-europe-61a68e250907fc8ePharmaRadar360en2026-09-21T13:00:00.000ZTwo new cholesterol drugs get their first global approval in Europehttps://www.pharmaradar360.com/article/fda-opens-expedited-drug-trial-pilot-to-cut-development-delays-f3806e23c82077dePharmaRadar360en2026-09-21T13:00:00.000ZFDA Opens Expedited Drug Trial Pilot to Cut Development Delayshttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharmaRadar360en2026-09-21T12:59:43.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/telix-tlx-lines-up-us-1-65b-cancer-drug-merger-and-a-big-revenue-jump-8adff125aee08116PharmaRadar360en2026-09-21T12:56:19.000ZTelix (TLX) lines up US$1.65B cancer drug merger—and a big revenue jumphttps://www.pharmaradar360.com/article/adrx-ipo-news-sirna-biotech-adarx-pharmaceuticals-sets-terms-for-350-million-ipo-7c6df0ecf3d07353PharmaRadar360en2026-09-21T12:50:00.000ZADRX IPO News - siRNA biotech ADARx Pharmaceuticals sets terms for $350 million IPOhttps://www.pharmaradar360.com/article/krystal-biotech-inc-bofa-global-research-raises-price-objective-to-400-from-392-76033b6bd017aee9PharmaRadar360en2026-09-21T12:46:51.000ZKRYSTAL BIOTECH, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $400 FROM $392https://www.pharmaradar360.com/article/us-china-biotech-licensing-expected-to-thrive-as-washington-softens-stance-news-7bfa8d1d5a5b74b0PharmaRadar360en2026-09-21T12:40:36.000ZUS-China Biotech Licensing Expected to Thrive as Washington Softens Stance - News and Statisticshttps://www.pharmaradar360.com/article/bofa-adjusts-price-target-on-krystal-biotech-to-400-from-392-keeps-buy-rating-3e1641c6da3c6b68PharmaRadar360en2026-09-21T12:34:44.000ZBofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Ratinghttps://www.pharmaradar360.com/article/factbox-weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competiti-5514ab11a1196d72PharmaRadar360en2026-09-21T12:28:02.000ZFactbox-Weight-loss drug developers line up to tap lucrative market as competition heats uphttps://www.pharmaradar360.com/article/rhelion-subsidiary-supplies-psilocybin-for-phase-3-palliative-care-trial-0d4d220a9ee9c49ePharmaRadar360en2026-09-21T12:11:57.000ZRhelion Subsidiary Supplies Psilocybin for Phase 3 Palliative Care Trialhttps://www.pharmaradar360.com/article/denmark-eyes-shortage-substitution-protocols-as-industry-urges-tight-limits-d1dc310ade3ee8dePharmaRadar360en2026-09-21T12:10:50.000ZDenmark eyes shortage substitution protocols as industry urges tight limitshttps://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92PharmaRadar360en2026-09-21T12:10:31.000ZCOVID-19 vaccine (5 years and over) PGD and VGDhttps://www.pharmaradar360.com/article/arch-biopartners-under-pressure-clinical-stage-biotech-faces-renewed-selling-as-327b8f6542f8321ePharmaRadar360en2026-09-21T12:09:00.000ZArch Biopartners Under Pressure: Clinical-Stage Biotech Faces Renewed Selling as Valuation Concerns Mounthttps://www.pharmaradar360.com/article/china-targets-25-of-global-first-in-class-drugs-by-2030-in-new-pharma-five-year-f8d103925f821267PharmaRadar360en2026-09-21T12:06:26.000ZChina targets 25% of global first-in-class drugs by 2030 in new pharma five-year-planhttps://www.pharmaradar360.com/article/phase-2-trial-suggests-vitamin-c-may-benefit-people-with-pre-cancer-blood-disord-64b38f62af9ca22ePharmaRadar360en2026-09-21T12:05:25.000ZPhase 2 trial suggests vitamin C may benefit people with pre-cancer blood disordershttps://www.pharmaradar360.com/article/filament-ships-psilocybin-drug-pex010-for-phase-3-trial-on-psychological-distres-00504eb35086a553PharmaRadar360en2026-09-21T12:03:26.000ZFilament ships psilocybin drug PEX010 for Phase 3 trial on psychological distress in palliative care.https://www.pharmaradar360.com/article/weight-loss-drug-developers-line-up-to-tap-lucrative-market-as-competition-heats-54efba15b344cc0fPharmaRadar360en2026-09-21T12:01:24.000ZWeight-loss drug developers line up to tap lucrative market as competition heats uphttps://www.pharmaradar360.com/article/pfizer-c-f-depot-licence-suspended-as-karnataka-probes-fake-drug-racket-eb671632b4449c57PharmaRadar360en2026-09-21T12:01:19.000ZPfizer C&F Depot Licence Suspended as Karnataka Probes Fake Drug Rackethttps://www.pharmaradar360.com/article/caplyta-lumateperone-shows-significant-and-rapid-improvement-in-bipolar-mania-in-14963d1b5f3d3bc5PharmaRadar360en2026-09-21T12:00:00.000ZCAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyhttps://www.pharmaradar360.com/article/trump-s-drug-price-plan-targets-foreign-freeloaders-but-shoots-american-innovato-5e14093c8aaa4a87PharmaRadar360en2026-09-21T12:00:00.000ZTrump’s drug price plan targets foreign freeloaders — but shoots American innovatorshttps://www.pharmaradar360.com/article/abbvie-and-iambic-announce-collaboration-to-accelerate-ai-driven-drug-discovery-6b060a185e233d47PharmaRadar360en2026-09-21T12:00:00.000ZAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discoveryhttps://www.pharmaradar360.com/article/psilocybin-doses-without-hallucinations-will-be-tested-in-end-of-life-care-6c1213d2afac37aePharmaRadar360en2026-09-21T11:49:00.000ZPsilocybin doses without hallucinations will be tested in end-of-life carehttps://www.pharmaradar360.com/article/virtual-biotech-employs-37-000-ai-agents-for-end-to-end-drug-development-8f7d97a93a576cdcPharmaRadar360en2026-09-21T11:46:42.000ZVirtual Biotech "Employs" 37,000 AI Agents for End-to-End Drug Developmenthttps://www.pharmaradar360.com/article/cyllene-appoints-seasoned-biotech-exec-as-cfo-74f91b753010fd2cPharmaRadar360en2026-09-21T11:40:15.000ZCyllene appoints seasoned biotech exec as CFOhttps://www.pharmaradar360.com/article/pharma-exports-continue-to-strengthen-the-swedish-economy-6d1e9ae333cb8b5fPharmaRadar360en2026-09-21T11:37:30.000ZPharma exports continue to strengthen the Swedish economyhttps://www.pharmaradar360.com/article/la-ema-y-hma-abren-el-proceso-de-comentarios-sobre-la-nueva-guia-de-eu-in-para-i-b9a7929b040a0936PharmaRadar360en2026-09-21T11:26:32.000ZLa EMA y HMA abren el proceso de comentarios sobre la nueva guía de EU-IN para investigadoreshttps://www.pharmaradar360.com/article/karnataka-minister-says-pfizer-c-f-agency-failed-to-aid-fake-drug-probe-d544ad166f836728PharmaRadar360en2026-09-21T11:23:03.000ZKarnataka Minister says Pfizer C&F agency failed to aid fake drug probehttps://www.pharmaradar360.com/article/cordis-project-community-based-scale-up-of-integrated-community-health-worker-le-05286051f35c02caPharmaRadar360en2026-09-21T11:22:51.000ZCORDIS project: COMMUNITY-BASED SCALE UP OF INTEGRATED COMMUNITY HEALTH WORKER-LED CARDIOVASCULAR RISK FACTOR MANAGEMENT - ComBaScalehttps://www.pharmaradar360.com/article/cordis-project-microwave-photonics-platform-for-cancer-detection-and-treatment-4e2c58f5b234309aPharmaRadar360en2026-09-21T11:22:44.000ZCORDIS project: Microwave photonics platform for cancer detection and treatmenthttps://www.pharmaradar360.com/article/cordis-project-the-interaction-between-chronic-pain-and-genetics-in-contributing-5d67fb178fa044eePharmaRadar360en2026-09-21T11:22:44.000ZCORDIS project: The interaction between chronic pain and genetics in contributing to cognitive impairmenthttps://www.pharmaradar360.com/article/cordis-project-towards-predictive-computational-platform-for-drug-solubilization-1268e26242a4e7b4PharmaRadar360en2026-09-21T11:22:43.000ZCORDIS project: Towards predictive computational platform for drug solubilization in the gastrointestinal tracthttps://www.pharmaradar360.com/article/cordis-project-controlling-reactive-species-delivery-in-cold-plasma-jets-a-key-c-7546c6a43992920dPharmaRadar360en2026-09-21T11:22:24.000ZCORDIS project: Controlling Reactive Species Delivery in Cold Plasma Jets: A key challenge in Plasma Medicinehttps://www.pharmaradar360.com/article/cordis-project-electrochemical-carboxylic-acid-exchange-for-sustainable-drug-dev-e80014a705f27d3bPharmaRadar360en2026-09-21T11:22:12.000ZCORDIS project: Electrochemical Carboxylic Acid Exchange for Sustainable Drug Developmenthttps://www.pharmaradar360.com/article/brazil-pharmaceutical-distributors-face-mounting-financial-pressure-2eeef9a7b9aca460PharmaRadar360en2026-09-21T11:20:54.000ZBrazil pharmaceutical distributors face mounting financial pressurehttps://www.pharmaradar360.com/article/sichuan-biokin-pharmaceutical-s-unit-receives-milestone-payment-from-bristol-mye-ca99112d5b22276bPharmaRadar360en2026-09-21T11:16:29.000ZSichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibbhttps://www.pharmaradar360.com/article/psychedelics-are-wall-street-s-next-trip-why-this-biotech-stock-is-already-up-20-52049d1cb6186539PharmaRadar360en2026-09-21T11:08:59.000ZPsychedelics Are Wall Street’s Next Trip. Why This Biotech Stock Is Already Up 200%.https://www.pharmaradar360.com/article/alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial-7d805f10ecf38946PharmaRadar360en2026-09-21T11:03:37.000ZAlkermes’ orexin agonist shows potential to treat ADHD in early-stage trialhttps://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-4e3af3cef35b6b21PharmaRadar360en2026-09-21T11:02:40.000ZSerbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Sciencehttps://www.pharmaradar360.com/article/serbian-biotech-startup-takes-its-journey-from-belgrade-to-cambridge-with-docume-993c912068e3ffbePharmaRadar360en2026-09-21T11:02:36.000ZSerbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Sciencehttps://www.pharmaradar360.com/article/tiziana-announces-last-patient-completes-last-visit-in-phase-2a-inform-ms-trial-121aeb1f6cd0e04cPharmaRadar360en2026-09-21T11:00:00.000ZTiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumabhttps://www.pharmaradar360.com/article/alkermes-announces-positive-phase-1b-results-demonstrating-clinical-proof-of-con-e143bd6657dbae3bPharmaRadar360en2026-09-21T11:00:00.000ZAlkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)https://www.pharmaradar360.com/article/how-inline-refractive-index-monitoring-can-improve-real-time-peptide-manufacturi-6daaaf2be2a7405bPharmaRadar360en2026-09-21T10:54:35.000ZHow inline refractive index monitoring can improve real-time peptide manufacturinghttps://www.pharmaradar360.com/article/singapore-draws-international-biotech-vcs-as-asia-pacific-life-sciences-sector-t-8b267d226e97ee94PharmaRadar360en2026-09-21T10:53:07.000ZSingapore draws international biotech VCs as Asia-Pacific life sciences sector takes offhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-co-ltd-to-go-ex-dividend-on-september-22nd-2026-with-7e95578a30c6b612PharmaRadar360en2026-09-21T10:48:19.000ZHANSOH PHARMACEUTICAL GROUP CO LTD To Go Ex-Dividend On September 22nd, 2026 With 0.03659 USD Dividend Per Sharehttps://www.pharmaradar360.com/article/merck-s-keytruda-qlextm-pembrolizumab-and-berahyaluronidase-alfa-pmph-approved-i-cb6eee590ac0416cPharmaRadar360en2026-09-21T10:45:00.000ZMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japanhttps://www.pharmaradar360.com/article/teva-nyse-teva-legal-chief-files-273k-share-sale-notice-e62f1c4bffd47859PharmaRadar360en2026-09-21T10:40:50.000ZTeva (NYSE: TEVA) legal chief files $273K share-sale noticehttps://www.pharmaradar360.com/article/tekpac-s-intelligent-packaging-increases-output-for-patch-manufacturer-5fc87af611260110PharmaRadar360en2026-09-21T10:30:15.000ZTekpac’s intelligent packaging increases output for patch manufacturerhttps://www.pharmaradar360.com/article/the-fda-has-approved-29-u-k-led-cancer-drugs-since-2021-now-a-u-k-regulator-will-a64efa1f5f19d8b7PharmaRadar360en2026-09-21T10:30:00.000ZThe FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review.https://www.pharmaradar360.com/article/os-therapies-completes-fda-type-c-statistical-methods-meeting-and-provides-updat-79fead0c1f7c2adfPharmaRadar360en2026-09-21T10:30:00.000ZOS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbishttps://www.pharmaradar360.com/article/lilly-secures-full-fda-nod-for-inluriyo-verzenio-breast-cancer-combo-986279ff4c2ee3b2PharmaRadar360en2026-09-21T10:29:49.000ZLilly secures full FDA nod for Inluriyo-Verzenio breast cancer combohttps://www.pharmaradar360.com/article/novo-buys-three-non-incretin-obesity-programs-from-kallyope-1771b5edb75f4697PharmaRadar360en2026-09-21T10:29:14.000ZNovo buys three non-incretin obesity programs from Kallyopehttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-aug-16bd5e27d65a23b1PharmaRadar360en2026-09-21T10:28:57.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: August 2026https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-2a4014b9e82727c7PharmaRadar360en2026-09-21T10:28:18.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/major-reform-of-eu-drug-regulations-what-will-change-for-patients-1b494b7bc3bbb314PharmaRadar360en2026-09-21T10:25:11.000ZMajor Reform of EU Drug Regulations: What Will Change for Patientshttps://www.pharmaradar360.com/article/metavallon-backs-parkinson-s-biotech-anacalypsis-in-first-of-its-kind-greek-deal-a0596c80e643d916PharmaRadar360en2026-09-21T10:14:29.000ZMetavallon backs Parkinson's biotech Anacalypsis in first-of-its-kind Greek dealhttps://www.pharmaradar360.com/article/research-collaboration-to-advance-a-novel-therapy-for-alzheimer-s-disease-f02f2d6a6aefabfcPharmaRadar360en2026-09-21T10:09:33.000ZResearch collaboration to advance a novel therapy for Alzheimer’s diseasehttps://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-pfizer-depot-7-other-firms-face-licence-suspens-3be6e17a0c46130aPharmaRadar360en2026-09-21T10:09:26.000ZKarnataka Busts Fake Drug Racket: Pfizer Depot, 7 Other Firms Face Licence Suspensionhttps://www.pharmaradar360.com/article/us-treasury-reportedly-drafting-rules-to-preserve-pharma-licensing-deals-with-ch-267bf55a61b7fc6aPharmaRadar360en2026-09-21T10:06:32.000ZUS Treasury reportedly drafting rules to preserve pharma licensing deals with Chinahttps://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3PharmaRadar360en2026-09-21T10:03:40.000ZXenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.https://www.pharmaradar360.com/article/cannabinoids-vs-opioids-is-chronic-pain-treatment-at-a-turning-point-6360efc5a5b20214PharmaRadar360en2026-09-21T10:00:34.000ZCannabinoids vs Opioids: Is Chronic Pain Treatment at a Turning Point?https://www.pharmaradar360.com/article/high-tide-of-china-biotech-deals-seen-as-us-curb-fears-fade-analysts-aaba7a319c133b2cPharmaRadar360en2026-09-21T10:00:10.000Z‘High tide’ of China biotech deals seen as US curb fears fade: analystshttps://www.pharmaradar360.com/article/adult-social-care-finance-report-england-2025-to-2026-edfdf55f46596236PharmaRadar360en2026-09-21T09:52:28.000ZAdult social care finance report, England: 2025 to 2026https://www.pharmaradar360.com/article/adult-social-care-activity-report-england-2025-to-2026-d04cfc1369caa66dPharmaRadar360en2026-09-21T09:52:21.000ZAdult social care activity report, England: 2025 to 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35PharmaRadar360en2026-09-21T09:51:42.000ZNational flu and COVID-19 surveillance report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-18-october-2026-673a62d4be0d46e6PharmaRadar360en2026-09-21T09:51:35.000ZWeekly all-cause mortality surveillance: week ending 18 October 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-43-report-data-to-week-42-data-up-t-d32e68d6017bb7c3PharmaRadar360en2026-09-21T09:51:27.000ZNational Norovirus and Rotavirus Report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2025-to-2026-625b82782f2a1916PharmaRadar360en2026-09-21T09:51:19.000ZCold mortality monitoring report, England: winter 2025 to 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-39-report-data-to-week-38-data-up-t-b701a0f0114ed05cPharmaRadar360en2026-09-21T09:50:07.000ZNational Norovirus and Rotavirus Report, week 39 report: data to week 38 (data up to 20 September 2026)https://www.pharmaradar360.com/article/d-d-pharmatech-s-head-of-r-d-park-eun-ji-newco-bridges-early-stage-biotech-firms-b72d729bb82a03d9PharmaRadar360en2026-09-21T09:45:05.000ZD&D Pharmatech’s Head of R&D Park Eun-ji,: “NewCo bridges early-stage biotech firms and big pharma”https://www.pharmaradar360.com/article/belgium-s-novadip-biosciences-raises-10-4-million-to-fund-pivotal-clinical-trial-1c00f7f63d3d96abPharmaRadar360en2026-09-21T09:40:43.000ZBelgium's Novadip Biosciences raises €10.4 million to fund pivotal clinical trial and unlock EIB loan tranchehttps://www.pharmaradar360.com/article/thousands-invited-to-register-for-public-panel-for-independent-commission-on-adu-52b360f1b8267410PharmaRadar360en2026-09-21T09:35:00.000ZThousands invited to register for Public Panel for Independent Commission on Adult Social Carehttps://www.pharmaradar360.com/article/3-chinese-biopharma-stocks-retail-investors-are-watching-for-licensing-deals-f9c5948024fb39f8PharmaRadar360en2026-09-21T09:24:08.000Z3 Chinese Biopharma Stocks Retail Investors Are Watching For Licensing Dealshttps://www.pharmaradar360.com/article/why-ultragenyx-pharmaceutical-inc-nasdaq-rare-is-in-focus-now-2794a473faf0e70fPharmaRadar360en2026-09-21T09:24:00.000ZWhy Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is In Focus Now?https://www.pharmaradar360.com/article/sarepta-therapeutics-srpt-stock-analysis-navigating-the-biotech-waters-with-a-fo-00f2039c62c0d646PharmaRadar360en2026-09-21T09:22:40.000ZSarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Waters with a Forward P/E of 7.64https://www.pharmaradar360.com/article/legend-biotech-corporation-legn-stock-analysis-unveiling-a-175-potential-upside-bcd9d089c6ca5a63PharmaRadar360en2026-09-21T09:22:01.000ZLegend Biotech Corporation (LEGN) Stock Analysis: Unveiling a 175% Potential Upside in Biotech Innovationhttps://www.pharmaradar360.com/article/krystal-biotech-inc-krys-stock-analysis-a-look-at-its-14-36-potential-upside-9a61874672731d38PharmaRadar360en2026-09-21T09:21:09.000ZKrystal Biotech, Inc. (KRYS) Stock Analysis: A Look At Its 14.36% Potential Upsidehttps://www.pharmaradar360.com/article/exelixis-inc-exel-stock-analysis-navigating-biotech-with-strong-revenue-growth-a-5788861c9117fa48PharmaRadar360en2026-09-21T09:21:08.000ZExelixis, Inc. (EXEL) Stock Analysis: Navigating Biotech with Strong Revenue Growth and Strategic Collaborationshttps://www.pharmaradar360.com/article/nuvalent-inc-nuvl-stock-analysis-navigating-the-biotech-landscape-with-a-clinica-7e778788f7bae560PharmaRadar360en2026-09-21T09:20:50.000ZNuvalent, Inc. (NUVL) Stock Analysis: Navigating the Biotech Landscape with a Clinical Focushttps://www.pharmaradar360.com/article/analysts-extremely-bullish-as-telix-beams-into-novartis-territory-with-1-6b-itm-130dcd4d2d8d5288PharmaRadar360en2026-09-21T09:19:06.000ZAnalysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisitionhttps://www.pharmaradar360.com/article/meningococcal-disease-enhanced-surveillance-form-969ec8a257418767PharmaRadar360en2026-09-21T09:15:58.000ZMeningococcal disease: enhanced surveillance formhttps://www.pharmaradar360.com/article/vertex-pharmaceuticals-vrtx-stock-analysis-a-biotech-powerhouse-with-11-97-poten-386828f0479eef3fPharmaRadar360en2026-09-21T09:15:23.000ZVertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 11.97% Potential Upsidehttps://www.pharmaradar360.com/article/mycoplasma-genitalium-antimicrobial-resistance-surveillance-mars-8b728d0038ccd66fPharmaRadar360en2026-09-21T09:14:36.000ZMycoplasma genitalium antimicrobial resistance surveillance (MARS)https://www.pharmaradar360.com/article/ukhsa-commercial-opportunities-9e4f936a0befa657PharmaRadar360en2026-09-21T09:09:06.000ZUKHSA commercial opportunitieshttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-21T09:06:32.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/karnataka-suspends-pfizer-c-f-depot-licence-in-fake-drug-case-warns-consumers-ov-61ae4f712869af8fPharmaRadar360en2026-09-21T08:58:23.000ZKarnataka suspends Pfizer C&F Depot licence in fake drug case, warns consumers over suspicious labels and QR codeshttps://www.pharmaradar360.com/article/daewon-pharmaceutical-brings-shinbaro-in-house-to-expand-south-korea-osteoarthri-06deb3f19266a298PharmaRadar360en2026-09-21T08:51:00.000ZDaewon Pharmaceutical brings Shinbaro in-house to expand South Korea osteoarthritis push - CHOSUNBIZhttps://www.pharmaradar360.com/article/cue-chalks-up-phase-2-hives-win-for-xolair-challenger-dca24fea5b2e4874PharmaRadar360en2026-09-21T08:50:00.000ZCue chalks up phase 2 hives win for Xolair challengerhttps://www.pharmaradar360.com/article/karnataka-spurious-drugs-racket-fda-cancels-16-drug-licences-suspends-pfizer-c-f-583b24989cc671cePharmaRadar360en2026-09-21T08:49:18.000ZKarnataka Spurious Drugs Racket: FDA Cancels 16 Drug Licences, Suspends Pfizer C&F Depot in Bidadihttps://www.pharmaradar360.com/article/retension-and-lilly-backed-trex-bio-both-set-out-plans-to-join-biotech-ipo-stamp-d978dc40cc95aef6PharmaRadar360en2026-09-21T08:29:34.000ZRetension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampedehttps://www.pharmaradar360.com/article/bofa-securities-lifts-sino-biopharmaceutical-target-to-hk-7-3-bullish-on-chinese-b25213c517e317dbPharmaRadar360en2026-09-21T08:26:00.000ZBofA Securities Lifts Sino Biopharmaceutical Target to HK$7.3, Bullish on Chinese Innovative Drug Globalization Momentumhttps://www.pharmaradar360.com/article/nykredit-a-s-takes-position-in-teva-pharmaceutical-industries-ltd-teva-8ef68b53d2f7b566PharmaRadar360en2026-09-21T08:12:45.000ZNykredit A S Takes Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/anthropic-bytedance-enter-ai-drug-discovery-the-next-coding-faces-critical-data-949e67c2cfec7bcbPharmaRadar360en2026-09-21T08:10:14.000ZAnthropic & ByteDance Enter AI Drug Discovery: The "Next Coding" Faces Critical Data Bottleneckshttps://www.pharmaradar360.com/article/aspen-achieves-top-10-ranking-for-integrated-reporting-excellence-11891286e263540bPharmaRadar360en2026-09-21T08:04:09.000ZAspen achieves Top 10 ranking for Integrated Reporting Excellencehttps://www.pharmaradar360.com/article/buy-sun-pharmaceutical-industries-target-of-rs-2070-geojit-financial-services-05d4bece45133dbaPharmaRadar360en2026-09-21T08:01:41.000ZBuy Sun Pharmaceutical Industries; target of Rs 2070: Geojit Financial Serviceshttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-may-202-2cc50be828051e6cPharmaRadar360en2026-09-21T07:54:02.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: May 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-39-report-data-to-week-38-dat-1bbeb1fdd2fcb78dPharmaRadar360en2026-09-21T07:43:06.000ZNational flu and COVID-19 surveillance report, week 39 report: data to week 38 (data up to 20 September 2026)https://www.pharmaradar360.com/article/aston-university-joins-forces-with-biotech-firm-to-develop-realistic-human-skin-5439803eb98b58fbPharmaRadar360en2026-09-21T07:39:58.000ZAston University joins forces with biotech firm to develop realistic human skin modelshttps://www.pharmaradar360.com/article/south-korea-s-inventera-reports-phase-3-success-for-mri-contrast-agent-plans-reg-7e38950a6ba7475bPharmaRadar360en2026-09-21T07:35:00.000ZSouth Korea's Inventera Reports Phase 3 Success for MRI Contrast Agent, Plans Regulatory Filing This Yearhttps://www.pharmaradar360.com/article/antengene-starts-phase-iii-clinch-3-trial-of-atg-022-in-advanced-gastric-cancer-02e84e96f3c002c3PharmaRadar360en2026-09-21T07:33:39.000ZAntengene Starts Phase III CLINCH-3 Trial of ATG-022 in Advanced Gastric Cancerhttps://www.pharmaradar360.com/article/china-plans-more-support-for-pharma-innovation-f77ec0948695270fPharmaRadar360en2026-09-21T07:09:45.000ZChina plans more support for pharma innovationhttps://www.pharmaradar360.com/article/inventera-s-mri-contrast-agent-passes-phase-3-trial-in-korea-22fdf31a869b455ePharmaRadar360en2026-09-21T06:53:52.000ZInventera's MRI Contrast Agent Passes Phase 3 Trial in Korea